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INTRODUCTION

In a country that boasts over one and a half million prisoners, the
American criminal justice system has become the second highest source of
referrals to treatment for drug dependency.' However, drug treatment within
the criminal justice system is still quite limited and often takes place in
programs such as drug courts.2 The overwhelming majority of drugdependent defendants ("justice-involved population") is either treated outside
the system or not treated at all. 3 Furthermore, research indicates that
incarceration in and of itself is inadequate to address drug dependency,
especially when compared with the overarching goal of incarceration to
reduce recidivism and make communities safer.4 These gaps become
increasingly visible at a time when the country is embroiled in an opioid
epidemic that is driven in part by illicit drug-seeking behavior.
South Carolina, much like the rest of the nation, is substantially affected
by this opioid epidemic. Not only has the state seen a sharp increase in opioidrelated overdose deaths and hospitalizations, but it has also experienced ripple
effects in its economy and criminal justice system. These effects were severe
enough that in December 2017, Governor Henry McMaster issued two
executive orders to address this public health emergency. One order directed
the South Carolina Department of Health and Human Services (DHHS) to

1.
See E. ANN CARSON, U.S. DEP'T OF JUSTICE, NCJ 251149, PRISONERS IN 2016
(2018); KELLEY SMITH & ALEXANDER STRASHNY, CTR. FOR BEHAVIORAL HEALTH
STATISTICS & QUALITY, CHARACTERISTICS OF CRIMINAL JUSTICE SYSTEM REFERRALS
DISCHARGED FROM SUBSTANCE ABUSE TREATMENT AND FACILITIES WITH SPECIALLY
DESIGNED CRIMINAL JUSTICE PROGRAMS 2 (April 26, 2016).

2.
"In 2011, there were 1.7 million discharges from substance abuse treatment programs.
Of these, about 588,000 discharges-or 34.4 percent were referred to treatment through the
criminal justice system. This was the second highest referral source following individual [and]
self-referrals. The largest share of criminal justice referrals was via probation/parole (35.9
percent), followed by state [and] federal[,] and other court referrals (15.7 and 14.3 percent,
respectively)." SMITH & STRASHNY, supra note 1, at 2.
3.
Redonna K. Chandler et al., Treating Drug Abuse and Addiction in the Criminal

Justice System: Improving PublicHealth and Safety, 301 J. AM. MED. Ass'N 183, 183 (2009)
(citation omitted).

4.

Id.
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limit initial opioid prescriptions for acute and post-operative pain to a
maximum of five days for state Medicaid recipients. 5 The second order
directed the creation of the South Carolina Opioid Emergency Response Team
(OERT). 6 Jointly led by the South Carolina Law Enforcement Division
(SLED) and the South Carolina Department of Alcohol and Other Drug Abuse
Services (DAODAS), the OERT is comprised of both state agencies and
private stakeholders. It is tasked with developing a multifaceted plan to
address the opioid emergency in South Carolina. Specifically, the OERT plan
suggests that Medically-Assisted Treatment (MAT), an evidence-based
practice to treat opioid use disorders (OUDs), is underutilized in South
Carolina in general, and in the state's criminal justice system in particular.'
Furthermore, since drug use and the criminal justice system are intimately
intertwined, it will benefit the state's criminal justice institutions to
incorporate these practices. This "all hands on deck" approach will not only
reduce opioid related overdose deaths but will also reduce recidivism and
make communities safer. This Article will outline the main historical events
that led to the opioid epidemic and how the criminal justice system can help
curb its effects on the state's justice-involved population.
II.

OPIOID-PROLIFERATION IN THE UNITED STATES

The current opioid-driven public health crisis in the United States did not
arise ex nihilo. Rather, this "perfect storm" of mega-scale addiction to opioids
and its destructive consequences has been in the making for almost three
decades. From 1999 to 2017, more than 700,000 Americans died from drug
overdoses, with opioids responsible for more than half of these deaths.' Over
this time period, experts argue that the United States experienced three
consecutive waves of opioid proliferation. 9 These waves are intrinsically
unique and distinguishable from each other in that they each revolve around
certain "types" of opioids and their diverse distribution methods.
Consequently, each wave presented a myriad of challenges for legislators,

5.
6.

S.C. Exec. Order No. 2017-43 (Dec. 18, 2017).
S.C. Exec. Order No. 2017-42 (Dec. 18, 2017).

7.

S.C. DEP'T OF ALCOHOL & OTHER DRUG ABUSE SERV., Focus AREA - TREAT AND

RECOVER Annex 3-1 (2018).
8.
Press Release, Centers for Disease Control and Prevention, New Data Show Growing
Complexity of Drug Overdose Deaths in America (Dec. 21, 2018).
9.

Understanding the Epidemic, CTRS. FOR DISEASE CONTROL & PREVENTION,

https://www.cdc.gov/drugoverdose/epidemic/index.html (last updated Dec. 19, 2018) (citation
omitted).
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educators, law enforcement agencies, and public health officials, who have
been engaged in containment efforts for nearly two decades.
A.

The First Wave

It was not until the start of the new millennium that the country realized
that it was embroiled in a large-scale public health crisis. In retrospect, it was
the rapid increase in drug overdose deaths from 1999 onward specifically
those attributed to short-acting pharmaceutical painkillers such as oxycodone,
hydrocodone, and hydromorphone-that caused leaders in the medical
community to question some of the established pain management guidelines.
Although these guidelines were originally intended to address the widespread
problems of underassessment and undertreatment of pain in patients, their
aggressive approach to pain eradication through the liberal use of opioids
contributed to overdose deaths and development of drug dependency in the
treated population.1 0 Moreover, further contributing to this upward trend of
opioid users were drug manufacturers, specifically Purdue Pharma. Shortly
after the formulation of OxyContin® in 1995, Purdue aggressively sought to
expand its use to "non-malignant pain markets."" Purdue's marketing tactics
included all-expenses-paid pain management conferences for prescribers and
a lucrative bonus system for its sales force. 12 Additionally, when selling the
"benefits" of OxyContin® to its medical prescribers, Purdue consistently
minimized the risks of opioid addiction in chronic pain patients who use pain
medicine daily and for a prolonged period of time. 13 Purdue repeatedly cited
studies in acute pain patients that showed that the development of addiction
to opioids is rare in medical patients with no history of addiction. 14 As a result,
between 1997 and 2002, dispensation of OxyContin" prescriptions for noncancer patients increased by almost tenfold, and the aggregated sales of the
medication ballooned from $44 million in 1996 to 2001 and in 2002,
combined sales of nearly $3 billion. '5 Notwithstanding Purdue's actions, it

10. DAVID W. BAKER, THE JOINT COMMISSION'S PAIN STANDARDS: ORIGINS AND
EVOLUTION 2 (2017).
11. Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph,
Public Health Tragedy, 99 AM. J. PUB. HEALTH 221, 222-23 (2009) (citing PURDUE PHARMA,
OXYCONTIN MARKETING PLAN (1998)).

12. Id. at 221-22 (citing U.S. Gov'T ACCOUNTABILITY OFFICE, GAO-04-110,
PRESCRIPTION DRUGS: OXYCONTIN ABUSE AND DIVERSION AND EFFORTS TO ADDRESS THE
PROBLEM (2003)).
13. Id. at 223 (citing U.S. GOV'T ACCOUNTABILITY OFFICE, supra note 12).
14. Id. (citing Jane Porter & Hershel Jick, Addiction Rare in Patients Treated with
Narcotics, 302 NEW ENG. J. MED. 123 (1980)).
15. Id. at 223 (citing U.S. Gov'T ACCOUNTABILITY OFFICE, supra note 12).
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certainly was not the only opioid manufacturer to enjoy a massive sales
growth. In fact, between 1991 and 2013, opioid prescriptions in the United
States rose from 76 million to 207 million per year.16
Notably, the pain guidelines and drug manufacturers were not the only
catalysts for this epidemic. Blame and liability must be extended to drug
wholesalers and pharmacies as well. As demand for opioids intensified,
pharmaceutical wholesalers, such as H.D. Smith and Miami-Luken, were
shipping exorbitant quantities of drugs all over the nation, while flagrantly
disregarding red flags.' 7 Take, for example, the case of Williamson, West
Virginia, a tiny town of three thousand residents in rural Appalachia, where
between 2008 and 2015, drug wholesalers shipped approximately 20.8 million
painkillers." Pharmacies, both chain and locally-owned, helped push these
drugs out to communities. Although pharmacists share a corresponding
responsibility with prescribers to ensure that prescriptions are issued for
legitimate medical purposes, they too, ignored red flags.1 9 In some instances,
pharmacists accepted dubious prescriptions that were written by out-of-state
physicians or failed to question obviously forged prescriptions. In other cases,
pharmacists filled out prescriptions for numerous opioids, benzodiazepines,
and tranquilizers, a combination that the pharmacists knew or should have
known would result in one of two outcomes for their patients: severe drug
dependency or overdose. 20 By the time the United States realized it was
experiencing an epidemic, addiction to opioids was already out of control.21
The government's efforts to stem the first tidal wave of opioid addiction
and overdose deaths culminated in the criminal prosecution of Purdue in 2007.

16. Nora D. Volkow, America's Addiction to Opioids: Heroin and Prescription Drug
Abuse (May 14, 2014) (transcript available at https://www.drugabuse.gov/aboutnida/legislative-activities/testimony-to-congress/2014/americas-addiction-to-opioids-heroinprescription-drug-abuse).
17. Laurel Wamsley, DrugDistributorsShipped 20.8 Million Painkillersto West Virginia
Town of 3,000, NPR (Jan. 30, 2018, 5:36 PM), https://www.npr.org/sections/thetwoway/2018/01/30/581930051,/drug-distributors-shipped-20-8-million-painkillers-to-westvirginia-town-of-3-00.
18. Id.
19. See e.g., Complaint TT 56-57, at 17, Kentucky v. Walgreens Boots Alliance, Inc., No.
18-CCI-00846 (Boone Cir. Ct. June 14, 2018).
20. See Sari Horwitz & Scott Higham, DEA Launches New Crackdown on Pharmacies
and
Opioid
Over-Prescribers,
WASH.
POST
(Jan.
30,
2018),
https://www.washingtonpost.com/world/national-security/dea-launches-new-crackdown-onpharmacies-and-opioid-over-prescribers/2018/01/30/14cc2Obe-0600- 11 e8-94e8-e8b8600ade23
story.html?noredirect=on&utmterm=.f8aaec803007.
21. See Leonard J. Paulozzi et al., Vital Signs: Overdoses of Prescription Opioid Pain
Relievers-UnitedStates, 1999-2008, 60 MORBIDITY & MORTALITY WKLY. REP. 1487, 1488
(2011) ("Substance abuse admission rate in 2009 was almost six times the rate in 1999.").
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The company and its executives "pleaded guilty to a felony charge of
'misbranding' OxyContin" while marketing the drug by misrepresenting,
among other things, its risk of addiction and potential to be abused." 22 The
company also agreed to pay $634.5 million in combined fines.2 3 Additionally,
law enforcement entities, such as the Drug Enforcement Administration
(DEA)'s Tactical Diversion Squads (TDS) and their state counterparts sought
aggressive criminal prosecutions of rogue doctors, drug distributors, and
pharmacies. Eventually, these combined efforts did result in reductions in the
prescription and dispensation of opioids. 24 That said, these efforts did very
little to address the widespread addiction to opioids. Moreover, the large
number of opioid-dependent individuals and the limited availability of
prescription opioids provided opportunities for criminal organizations to push
a cheaper and more potent opioid product: heroin.25
B.

The Second Wave

The rise in heroin use brought with it a second wave of opioid saturation,
which peaked by 2013. From 2002 to 2013, heroin-related overdoses
increased by 286%, with more than eighty percent of users admitting to the
misuse of prescription opioids before initiating heroin use. 26 Furthermore, this
newly imported heroin was quite different than the "stepped-down,"
Colombian-sourced, white-powder heroin to which users were accustomed.27
This new heroin was black, tar-like sticky, and extremely potent, reaching
purity levels between sixty percent and eighty-four percent.28 Additionally,
unlike the Colombian-sourced heroin, the majority of this heroin was

22. Barry Meier, Originsofan Epidemic: PurduePharmaKnew Its Opioids Were Widely
Abused, N.Y. TIMES (May 29, 2018), https://www.nytimes.com/2018/05/29/health/purdueopioids-oxycontin.html.
23. Id.
24. See Anne Schuchat et al., New Data on Opioid Use and Prescribingin the United
States, 318 J. AM. MED. ASS'N 425, 425 (2017) (citing Gery P. Guy Jr. et al., Vital Signs:
Changes in OpioidPrescribingin the United States, 2006-2015, 66 MORBIDITY & MORTALITY
WKLY. REP. 697, 698 (2017)).
25. Lindsy Liu et al., History of the Opioid Epidemic: How Did We Get Here?, NAT'L
CAP. POISON CTR., https://www.poison.org/articles/opioid-epidemic-history-and-prescribingpatterns-182 (last visited Mar. 29, 2019).
26. Id.
27. See Sarah G. Mars et al., The Textures ofHeroin: User Perspectiveson "Black Tar"
and Powder Heroin in Two U.S. Cities, 48 J. PSYCHOACTIVE DRUGS 270 (2016) (citation
omitted).
28. Press Release, U.S. Dep't of Justice, Nearly 200 Arrested in Multi-Million Dollar
Heroin
Smuggling
Operation
(June
15,
2000),
https://www.justice.gov/archive/
opa/pr/2000/June/34 1crm.htm.
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cultivated by Mexican organizations and exported from a small state in
western Mexico called Nayarit. 29 Most importantly, it was considerably
cheaper than other heroin products or prescription drugs, and its suppliers
made it highly accessible to consumers by utilizing a pizza shop "home
delivery" like system. 30 Unfortunately, although federal and local law
enforcement agencies had invested considerable resources to stem the supply
of black tar heroin, these efforts came up short and only provided anecdotal
solutions at best. 3 1

C.

The Third Wave

Alongside the rise in the demand for heroin, in 2013, the United States
began experiencing a third wave of opioid proliferation, this time involving
synthetic opioids such as fentanyl. Fentanyl "is 50 to 100 times more potent
than morphine." 32 It is classified as a Schedule II drug, with a great potential
for abuse and dependency. 33 In appropriate medical settings, fentanyl is
prescribed in microgram dosages, mainly by oncologists, to treat pain in
cancer patients.34 On the illicit side, fentanyl and other synthetic opioids are
manufactured clandestinely and range in variety to include drugs such as
furanylfentanyl, acrylfentanyl, and carfentanil, an elephant tranquilizer that is
100 times more potent than fentanyl. 35 The Centers for Disease Control and
Prevention (CDC) has estimated that from November 2016 to November 2017
synthetic opioids were responsible for more than 27,000 overdose deathsmore than prescription drugs and heroin combined. 36 According to the DEA,

29. See id.
30. E.g., Christine Lagorio, DEA Busts 'Home-Delivery'HeroinRing, CBS NEWS (Aug.
15, 2006, 4:42 PM), https://www.cbsnews.com/news/dea-busts-home-delivery-heroin-ring.
31. See generally SAM QUINONES, DREAM LAND 317 (2016) (discussing how law
enforcement efforts to stem the flow of black tar heroin from Mexico were unsuccessful).
32.

What

is

fentanyl?

U.S.

CTRS.

FOR

DISEASE

CONTROL

&

PREVENTION,

https://www.cdc.gov/drugoverdose/opioids/fentanyl.html (last updated Dec. 19, 2018).
33. See U.S. DEP'T OF JUSTICE, CONTROLLED SUBSTANCES (2018) [hereinafter
CONTROLLED
SUBSTANCES
LIST],
https://www.deadiversion.usdoj.gov/schedules/
orangebook/c csalpha.pdf.
34. See Fentanyl, U.S. DRUG ENF'T ADMIN., https://www.dea.gov/factsheets/fentanyl

(last visited Mar. 29, 2019).
35. UTTAM DHILLON, U.S. DRUG ENF'T ADMIN., 2018 NATIONAL DRUG THREAT
ASSESSMENT 21, 32 (2018).
36. Health Alert Network, Rising Numbers of Deaths Involving Fentanyl and Fentanyl
Analogs, Including Carfentanil, andIncreasedUsage andMixing with Non-opioids, U.S. CTRS.
FOR
DISEASE
CONTROL
&
PREVENTION
(July
11,
2018,
1:00
PM),
https://emergency.cdc.gov/han/hanOO413.asp (citing Vital StatisticsProvisionalDrug Overdose
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most of these illicit synthetic opioids are likely manufactured in China.3 7 They
enter the country in parcel packages directly from China or from China
through Canada, or they are smuggled across the southwest boarder from
Mexico.38 Once in the country, these smuggled drugs are usually distributed
via domestic mail services.3 9 From a law enforcement perspective, the parceldelivery methods make the interdiction of U.S.-bound packages containing
China-sourced fentanyl and fentanyl analogues extremely difficult. Findings
from a 2018 bipartisan congressional report from the United States Senate
Permanent Subcommittee on Investigations revealed that in 2017 more than
318 million packages entered the United States without containing any
Advanced Electronic Data (AED). 40 This means that the United States Postal
Service and other federal authorities had no way of knowing who sent these
packages, where these packages were going, or what these packages
contained. 41 Consequently, the congressional report provided suggestions for
improving the detection of packages containing illicit drugs; 42 however, their

implementation is likely to take considerable time and would require
extensive cooperation with countries such as China.
III. THE OPIOID EPIDEMIC IN SOUTH CAROLINA

A. In Numbers
Affected by all three waves, South Carolina was not spared from the
epidemic's path of destruction. With respect to prescribing practices, data
from the South Carolina Prescription Drug Monitoring Program (PDMP)
confirms that an alarming number of opioids are dispensed every year across
the state. 43 Between 2014 and 2017, South Carolina averaged 4.54 million

Death

Counts,

U.S.

CTRS.

FOR

DISEASE

CONTROL

&

PREVENTION,

https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (last updated Feb. 13, 2019).
37. DRUG ENF'T ADMIN., U.S. DEP'T OF JUSTICE, DEA-DCT-DIR-001-17, vii, 68
(2016).
38. Id. at 68, 70.
39. Id.
40. STAFF OF S. SUBCOMM. ON INVESTIGATIONS, 115TH CONG., COMBATTING THE
OPIOID CRISIS: EXPLOITING VULNERABILITIES IN INTERNATIONAL MAIL 6 (Comm. Print

2018).
4 1. Id.
42. Id. at 11-13.
43. The program, which is housed by the South Carolina Department of Health and
Environmental Control (DHEC), Bureau of Drug Control, was established in 2006 pursuant to
the passage of the South Carolina Prescription Monitoring Act. S.C. CODE ANN. § 44-53-16 10
(2018). The Act's stated purpose is to "improve the state's ability to identify and stop the illegal

https://scholarcommons.sc.edu/sclr/vol70/iss3/11
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opioid prescriptions per year.44 This amount is quite remarkable considering
the state's population consists of only 4.9 million people, a factor that ranked
South Carolina sixth in the nation for opioid prescriptions per capita. 45 This
data has a strong correlation to the state's mortality information from DHEC's
division of Vital Statistics and the National Institute on Drug Abuse: from
2013 to 2017 opioid-related overdose death rates in the state tripled, from 5.2
to 15.5 deaths per 100,000 persons (from 247 total deaths in 2013 to 748 in
2017).46 The main contributor to this sharp upsurge was fentanyl-related
deaths, which increased by 179% (from 130 to 362 deaths) between 2015 and
2017.47 Furthermore, between 2014 and 2017, hospitalizations due to opioid
overdose increased by forty-eight percent, from 7,633 patients in 2014 to
10,873 patients in 2017.48 And finally, first responders' utilization of
naloxone, an opioid overdose antidote, soared by seventy-three percent, from
4,187 in 2014 to 7,278 in 2017.49
B.

In Legislation

Concerned with this public health crisis, the South Carolina General
Assembly has taken several legislative steps to address the multifarious nature
of this epidemic. In 2014, the state legislature passed Senate Bill 840, which
modified the requirements for drug dispensers to report to the PDMP on a
daily rather than monthly basis.50 This change not only increased the
efficiency of the PDMP to track data in real time, but it also positively

diversion of prescription drugs . .
" Id. § 44-53-1620. The PDMP mandates that dispensers
report any and all prescriptions of Schedule II, III, and IV drugs to the program's database. Id
§ 44-53-1640 (2018 & Supp. 2018).
44. South Carolina Opioid Summary, NAT'L INST. ON DRUG ABUSE,
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/south-carolinaopioid-summary (last updated Feb. 2018) (citing XPONENT, IMS HEALTH (2016)).
45. See Opioid Summaries by State, NAT'L INST. ON DRUG ABUSE,
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state (last updated Feb.
2018).
46. See South Carolina Opioid Summary, NAT'L INST. ON DRUG ABUSE,
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/south-carolinaopioid-summary (last updated Feb. 2018); S.C. DEP'T OF HEALTH & ENvTL. CONTROL, DRUG
OVERDOSE DEATHS: SOUTH CAROLINA (2017).
47. S.C. DEP'T OF HEALTH AND ENVTL. CONTROL, supra note 46.

48. Statistical data on file with the author.
49. Arnold Alier, Division Director of SC DHEC Bureau of EMS, Roundtable at the 51st
Annual Conference of the South Carolina Association of Counties: South Carolina Opioid
Epidemic
(Aug.
6,
2018)
(available
at
http://www.sccounties.org/Data/Sites/
1/media/meetings/annual-conference/presentations/2018/opioid-roundtable-alier.pdf).
50. S. 840, 120th Gen. Assemb., Reg. Sess. (S.C. 2014).
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'

impacted law enforcement's abilities to investigate cases involving forged
prescriptions or apprehend individuals who unlawfully receive similar
medications from multiple prescribers ("doctor shopping"). The following
year, the legislature passed the South Carolina Overdose Prevention Act. 5
This Act sought to provide civil and criminal immunity to prescribers,
pharmacists, caregivers, and first responders who engage in the prescription,
dispensation, and administration of naloxone in suspected opioid overdose
cases. 52 The Overdose Prevention Act paved the way for the development of
critical preventative programs, such as the South Carolina Law Enforcement
Officer Naloxone (LEON) program. Funded by DAODAS and deployed by
DHEC, LEON trains law enforcement officers to recognize the signs and
symptoms of an opioid-related overdose and further equips them with
naloxone to administer.53 In the two full years that LEON has been
operational, the program has trained more than 7,600 law enforcement
officers from over one hundred law enforcement agencies in all forty-six
counties in South Carolina. 54 Collectively, these trained law enforcement
officers have administered the life-saving drug more than 580 times, saving
the lives of close to 560 South Carolinians.5 5
In 2016, the General Assembly amended the Overdose Prevention Act to
allow for a state-wide standing order for naloxone. 56 As a prescription-only
drug, naloxone ordinarily requires consultation with a physician before it can
be obtained. However, the statewide standing order eliminates that
requirement and essentially shifts the status of naloxone to a "behind-thecounter" medication.5 7 During the 2018 legislative session, the Overdose
Prevention Act was amended again to include immunity for "Community
Distributors." 5 The law defines Community Distributors as "organization[s],
either public or private that provide substance use disorder assistance and
services, such as counseling, homeless services, advocacy, harm-reduction,
alcohol and drug screening, and treatment to individuals at risk of
experiencing an opioid-related overdose." 59 In its 2018 report, the South
Carolina House Opioid Abuse Prevention Study Committee noted that chronic
illicit opioid users are not likely to spend money on naloxone or to walk into

51. S.C. CODE ANN. § 44-130-10 (2018).
52. Id. §§ 44-130-30 to -60 (2018).
53. Opioid Epidemic, S.C. DEP'T OF HEALTH AND
https://www.scdhec.gov/opioid-epidemic (last visited Mar. 29, 2019).
54. Statistical data on file with the author.
55. Statistical data on file with the author.
56. H.R. 5193, 12 1st Gen. Assemb., Reg. Sess. (S.C. 2016).
57. See § 44-130-40.
58. H.R. 4600, 122nd Gen. Assemb., Reg. Sess. (S.C. 2018).
59. S.C. CODE ANN. § 44-130-20(2) (Supp. 2018).

https://scholarcommons.sc.edu/sclr/vol70/iss3/11
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pharmacies to obtain it.60 Because Community Distributors tend to come into
daily contact with this vulnerable population, the law now permits these
organizations to purchase naloxone in bulk, without the need for the
medication to be patient-specific, and to distribute it according to the
prescribed guidelines. 6 1

IV.

THE SCIENCE OF ADDICTION

In its final 2018 report, the House Opioid Abuse Prevention Study
Committee also recommended expanding access to Medically Assisted
Treatment (MAT). 62 Years of medical research and numerous studies have
confirmed MAT's effectiveness over abstinence-based treatment for opioid
dependency.63 However, understanding its efficacy requires a basic
knowledge of the science of opioid addiction and the evolution of addiction
treatment. Essentially, opioids activate areas in the brain and central nervous
system that decrease the perception of pain, while at the same time increasing
feelings of pleasure, euphoria, and relaxation.64 It is the latter set of reactions
that leads so many into addiction. 65 Often times, it begins with a legitimate
use of opioids to control pain or a brief experimental use for recreational
purpose. 66 As use of the opioids continues, the brain cells adapt to the intake
dosage and begin to develop tolerance, which then requires a larger intake of
opioids to achieve the same effects.67 This, in turn, forms a complete physical
dependency with severe withdrawal symptoms that can lead to an unrelenting
drug-seeking behavior. 68 This physiological transformation is scientifically
researched and proven, as both the American Society of Addiction Medicine

60. S.C. H.R. OPIoID ABUSE PREVENTION STUDY COMM., FINAL REPORT, H.R. 122, at
14(2018).
61. See S.C. CODE ANN. § 44-130-70 (Supp. 2018).
62. S.C. H.R. OPIOID ABUSE PREVENTION STUDY COMM., supra note 60, at 17.
63. See generally Bjarn Axel Johansson et al., Efficacy of Maintenance Treatment with
Naltrexone for Opioid Dependence: A Meta-analytical Review, 101 ADDICTION 491 (2006);
Lisa A. Marsch, The Efficacy of Methadone Maintenance Interventions in Reducing Illicit

Opiate Use, HIV Risk Behavior and Criminality:A Meta-Analysis, 93 ADDICTION 515 (1998);
Richard P. Mattick et al., Buprenorphine Maintenance Versus Placebo or Methadone
Maintenancefor Opioid Dependence, 2 COCHRANE DATABASE OF SYSTEMATIC REVS. at 1, 2

(Feb. 6, 2014).
64. See PrescriptionPain Medications (Opioids), NAT'L INST. DRUG ABUSE FOR TEENS,
https://teens.drugabuse.gov/drug-facts/prescription-pain-medications-opioids
(last updated

Mar. 19,
65.
66.
67.
68

2017).
Id
Id
Id.
Id.
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and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5), classify addiction as a "primary, chronic disease" of the brain.69
A.

Drug Addiction as ChronicDisease

The use of the term "chronic" to describe addiction is not accidental.
Other chronic diseases, such as diabetes and high cholesterol, require longterm and comprehensive treatments, often spanning patients' entire
lifetimes. 70 Whether these diseases are acquired at birth or later in life, their
treatments are multi-layered and include not only medications, but also
specific diets, exercise regimens, and lifestyle choices. 7 ' Furthermore,
patients who suffer from these chronic diseases are cared for and treated by a
slew of professionals, including physicians, nurses, pharmacists, dieticians,
psychologists, psychiatrists, and fitness trainers. In this respect, addiction is
no different. Whether developed as the result of recreational drug use or the
legitimate treatment of pain, once it is fully developed and manifested in a
person, a multi-prong approach is needed to address it, and MAT functions as
a crucial component of this approach.
The comparisons between OUD and other chronic diseases continue
beyond the classification level. Similar to chronic diabetic patients without
access to insulin, for example, OUD patients without access to medications
are proven to have an increased chance of relapse and a reduced chance of
remaining in treatment. 72 Furthermore, like chronic patients with high
cholesterol who take statins as instructed but disregard their dietary
instructions, 73 OUD patients who take medication but do not engage in
behavioral treatment may not achieve the maximum benefits from MAT. The
same comparative analysis applies to other common adverse factors shared by

69. TREATING OPIOID ADDICTION AS A CHRONIC DISEASE, AM. Soc'Y ADDICTION
MED. (Nov. 7, 2014), https://www.asam.org/docs/default-source/advocacy/cmm-fact-sheet--11-07-14.pdf. See generally THE DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS 540-46 (Am. Psychiatric Ass'n 5th ed., 2013) (regarding addiction generally).
70. See Drug Abuse and Addiction: One ofAmerica's Most Challenging Public Health
Problems, NAT'L INST. ON DRUG ABUSE, https://archives.drugabuse.gov/publications/drugabuse-addiction-one-americas-most-challenging-public-health-problems/addiction-chronic-dis
ease (last visited Mar. 29, 2019).
71. Id.
72. See Hilary Smith Connery, Medication-Assisted Treatment of Opioid Use Disorder:
Review ofthe Evidence and FutureDirections,23 HARV. REV. PSYCHIATRY 63, 66 (2015).
73. Janet Lubman Rathner, Statin MedicationsAre Not a Blank Checkfor Eating Poorly,
LABORERS'
HEALTH
&
SAFETY
FUND
OF
N.
AM.,
(July
2014),
https://www.lhsfna.org/index.cfm/lifelines/july-2014/statin-medications-are-not-a-blank-check
-for-eating-poorly.
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chronic diseases, such as the lack of supervision by medical professionals,
improper dosing of medication, lack of emotional and social support, and the
fear of stigma. As a result of such commonplace factors, a well-planned OUD
recovery program that includes behavioral treatment, access to an FDAapproved medication for OUD treatment, and wrap-around services (e.g.,
housing, Peer Support Specialists) provides the greatest chance to
successfully address this chronic disease.
B.

Medically Assisted Treatment: Methadone, Buprenorphine and
Naltrexone

At the time of this Article's publication, the FDA has approved three
different medications for treating OUD. 74 The first, methadone, is the most
studied of the three and dates back to the wave of opioid addiction that washed
across the country in the 1970s. 75 During that period, the United States faced
an influx of opioid-related drug use, addiction, and crime. In response, the
Nixon administration dramatically increased federal funding to stem the
supply of illicit opioids mainly heroin-entering the United States.76 A fact
less known is that the Nixon administration also provided funding for demand
reduction.7 7 In his June 1971 address to Congress, President Nixon argued
that "[w]e must rehabilitate the drug user if we are to eliminate drug abuse
and the antisocial activities that flow from drug abuse."78 Consequently, the
Nixon Administration funded the development of the methadone programs. 79
Although methadone was initially developed by German scientists during
World War II to handle a morphine shortage, researchers did not realize its
therapeutic attributes for opioid addiction until the 1960s.so As a full opioid
agonist" medication, methadone produces reactions in the brain similar to

74. Information about Medication-Assisted Treatment (MA T), FOOD & DRUG ADMIN.,
https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm600092.htm
(last
updated Feb. 13, 2019).
75. Soldiers, Hippies and Richard Nixon-An American History of Methadone, CRC
HEALTH,
https://www.crchealth.com/addiction/heroin-addiction-treatment/heroin-detox/his
torymethadone (last visited Mar. 29, 2019) [hereinafter CRC HEALTH].
76. Id
77. See id.
78. Richard M. Nixon, U.S. President, Special Message to the Congress on Drug Abuse
Prevention
and
Control
(June
17,
1971)
(transcript
available
at
https://library.cqpress.com/cqalmanac/document.php?id=cqal71-869-26707-1255187).
79. CRC HEALTH, supra note 75.
80. See id.
81. Agonist, partial-agonist and antagonist describe the strength of interaction between
the medication and the affected brain-cells. Opioid agonist medications latch on to the opioid
receptors stronger and therefore produce greater interaction with these receptors. See Jeffrey
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other opioids. However, what sets it apart from heroin and other "shortacting" opioids is its longer half-life, which reduces withdrawal symptoms
and cravings for opioids in chemically-dependent patients. 82 More
importantly, researchers found methadone does not produce the same
euphoric and tranquilizing effects as other opioids when properly dosed
in OUD patients.83 Collectively, these factors have been shown to reduce
drug-seeking behavior in OUD patients and increase patients' engagement in
productive lifestyles. 84 With almost fifty years of implementation, methadone
treatment is one of the most researched approaches to treating opioid
addiction. It is considered by the federal government as well as the medical
and treatment communities-to be the "gold standard" for OUD treatment."
Today, methadone maintenance treatment (MMT) programs dispense the
medication to their patients daily in a liquid form to maximize its dosing
effects on individual patients.8 6 The programs also incorporate behavioral
treatment, as federal and state regulations mandate that patients meet with
treatment counselors and medical professionals before receiving the
medication or continuing with an MMT program. 7
In 2002, the FDA approved a second medication for OUD treatment,
buprenorphine."8 Recognized primarily by its brand names Subutex© and
Suboxone©, it is a long-acting, but partial-agonist, opioid.8 9 Since its approval,
numerous studies have demonstrated the efficacy of buprenorphine as a
medication for maintenance treatment in opioid-dependent individuals. 90
Similar to methadone, the long half-life of the medication helps curb opioid
withdrawal symptoms, thereby mitigating the risks for relapse and overdose. 9

Fudin, Opioid Agonists, PartialAgonists, Antagonists: Oh My!, PHARMACY TIMES (Jan. 6,
2018, 1:00 PM), https://www.pharmacytimes.com/contributor/jeffrey-fudin/2018/01/opioidagonists-partial-agonists-antagonists-oh-my (discussing the different categories of opioids).
82. Marsch, supra note 63, at 515.
83. Id. at 515-16 (citations omitted).
84. Id. at 515.
85. Connery, supra note 72, at 63.
86. Justin J. Sanders et al., Meaning andMethadone: A Modelfor PromotingAdherence
in MMT, Based on Patients' Perceptions, ADDICTION TREATMENT F. (Nov. 15, 2013),
http://atforum.com/2013/11,/meaning-and-methadone-a-model-for-promoting-adherence-inmmt-based-on-patients-perceptions.
87. 42 C.F.R. § 8.12(f)(2) (2018); S.C. CODE ANN. REGS. § 61-4.1011 (Supp. 2018).
88. CTR. FOR SUBSTANCE ABUSE TREATMENT, CLINICAL GUIDELINES FOR THE USE OF
BUPRENORPHINE IN THE TREATMENT OF OPIOID ADDICTION 2 (2004).

89. See id.
90. E.g., Mattick, supra note 63, at 2.
91. See Xiaofan Li et al., BuprenorphinePrescribing: To Expand or Not to Expand, 22
J. PSYCHIATRIC
PRAC.
183-92, at 3 (2016), https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC4852384.
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However, unlike methadone, federal law caps buprenorphine prescribers at a
certain number of patients, and authorization from the DEA is required to
increase a prescriber's patient census. 92 "In 2000, Congress passed the Drug
Abuse Treatment Act of 2000 (DATA 2000), which permitted qualified
prescribers to obtain a waiver to treat opioid addiction with Schedule III-V
medications." 93 The waiver allowed practitioners to engage in opioid-based
treatment directly from their offices and "outside the traditional setting of the
[MMT] programs." 94 In capping the number of patients, Congress expressed
its concerns about abuse and diversion of buprenorphine that might be
associated with increased accessibility and wider availability. 95 In 2006,
Congress raised the limit to one hundred patients per prescriber, and did so
once more in 2016 to a maximum of 275 patients for qualifying prescribers. 96
Unfortunately, even with the cap increases, the shortage in buprenorphine
prescribers is quite noticeable. Recent studies point out that an estimated fiftythree percent of the counties in the United States do not have a single
prescriber with a DEA DATA waiver. 97
While the current push to make buprenorphine more available nationwide
is in full swing, practitioners and OUD patients can also consider the FDAapproved naltrexone as a third option. Although developed in 1963 and
patented in 1967, naltrexone did not receive FDA approval until 1984-and
its approval only occurred after the National Institute on Drug Abuse (NIDA)
stepped in and offered substantial funding to cover the costs of its clinical
development.98 Interestingly, NIDA originally developed naltrexone as
medication to treat alcohol dependency. Research confirmed its efficacy in
decreasing the amount and frequency of alcohol consumption in alcohol-

92. Id. at 4.
93. Id. Qualified prescribers include physicians, nurse practitioners (NPs) and physician
assistants (PAs). Qualifyfor Nurse Practitioners(NPs) and PhysicianAssistants (PAs) Waiver,
SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., https://www.samhsa.gov/programscampaigns/medication-assisted-treatment/training-materials-resources/qualify-np-pa-waivers
(last updated Mar. 4, 2019).
94. Li et al., supra note 91, at 4.
95. Cf id. at 8 (noting the authors' concerns of inevitable abuse).
96.
SERVS.

See Apply to Increase Patient Limits, SUBSTANCE ABUSE & MENTAL HEALTH
ADMIN.,
https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-

waiver-management/increase-patient-limits (last updated Feb. 9, 2017); see also 42 C.F.R.

§ 8.620 (2018).
97. Roger A. Rosenblatt et al., Geographic andSpecialty Distributionof US Physicians
Trained to Treat Opioid Use Disorder, 13 ANNALS OF FAM. MED. 23, 24 (2015).
98. See NAT'L INST. ON DRUG ABUSE, NARCOTIC ANTAGONISTS: NALTREXONE
PHARMACOCHEMISTRY AND SUSTAINED-RELEASE PREPARATIONS 8 (1981); JOSEPH WOUK,
GOOGLE: LDN! How AN OVERLOOKED DRUG RELIEVES CANCER, MS, AND IMMUNE SYSTEM
DISORDERS FOR A DOLLAR A DAY 78-79 (2008).
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dependent patients. 99 In treating OUDs, naltrexone is approved for
administration either as a daily oral dose in pill form or as a monthly
intermuscular injection (Vivitrol©). Unlike the opioid-agonists methadone and
buprenorphine, naltrexone is an opioid-antagonist medication. It attaches to
the brain's opioid receptors and creates a barrier that blocks opioid molecules
from attaching to the receptors.' 00 Furthermore, as an opioid antagonist,
naltrexone is not subject to misuse, diversion, or risks of overdose on its own.
However, among the three FDA-approved medications, naltrexone has the
most complicated process for induction into treatment. To avoid severe opioid
withdrawal, candidates for naltrexone treatment must be free of all opioids
prior to dosing, which can typically take seven to fourteen days.' 0
Consequently, research indicates that prolonged symptoms of opioid
withdrawal during washout do pose a higher risk for treatment dropout and

relapse.
C.

102

The Choice

With all three FDA-approved medications available in some capacity to
OUD patients across the country, the ultimate decision as to which is the
appropriate medical therapy is made by and between the patient and the
treating practitioner. This approach is consistent with decision-making
processes associated with other chronic diseases. For example, treatment
options for elevated cholesterol levels can range from simple dietary changes
to intake of a daily dose of medication to surgery, any of which may be
considered by patients pursuant to an informed decision-making process with
their treating practitioners. OUD patients still face many obstacles that greatly
diminish their access to MAT services, from the "shame" that frequently
accompanies drug addiction to the inappropriate stigma that is associated with
methadone treatment programs-or even the sheer unavailability of DATAwaivered buprenorphine prescribers. As will be discussed below, MAT

99. Henry R. Kranzler & Jeffry Van Kirk, Efficacy ofNaltrexone and Acamprosatefor
Alcoholism Treatment: A Meta-Analysis, 25 ALCOHOLISM: CLINICAL & EXPERIMENTAL RES.,
1335, 1335 (2001) (first citing James C. Garbutt et al., PharmacologicalTreatment ofAlcohol
Dependence: A Review of the Evidence, 281 J. AM. MED. Ass'N 1318, 1318-25 (1999); and
then citing Henry R. Kranzler, Pharmacotherapyof Alcoholism: Gaps in Knowledge and
Opportunitiesfor Research, 35 ALCOHOL & ALCOHOLISM 537, 537-47 (2000)).
100. How Vivitrol Works, VIVITROL, https://www.vivitrol.com/opioid-dependence/howvivitrol-works (last visited Mar. 29, 2019).
101. Connery, supra note 72, at 68.
102. Stacey C. Sigmon et al., OpioidDetoxification and Naltrexone Induction Strategies:
Recommendationsfor Clinical Practice,38 AM. J. DRUG & ALCOHOL ABUSE 187, 187 (2012)
(footnotes omitted).
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services accessibility is further complicated when the criminal justice system
is involved.
V.

MEDICALLY ASSISTED TREATMENT IN THE CRIMINAL JUSTICE SYSTEM

The criminal justice system in the United States has been late to
incorporate MAT into the treatment of defendants with an underlying OUD.
In 2013, the National Association of Drug Court Professionals (NADCP)
found that nearly half of the country's drug courts do not use medications in
their programs due to a lack of awareness or familiarity with MAT.1 03 This
result occurred even though the NADCP-several years prior-issued a
unanimous resolution urging drug courts to learn the facts about MAT and
obtain expert consultation from duly trained addiction psychiatrists or
addiction physicians.1 04 Furthermore, in its Adult Drug Court Best Practices
Standards, the NADCP concludes that MAT can "significantly improve
outcomes for" offenders, and "has been shown to significantly increase
[opioid-dependent] inmates' engagement in treatment; reduce illicit [opioid]
use; reduce rearrests, technical parole violations, and reincarceration rates;
and reduce mortality and hepatitis C infections." 0 5 Of course, drug courts, as
post-plea diversionary programs, represent only a minuscule fraction of cases
in the criminal justice system as a whole. As a result, the fact remains that
every year the vast majority of chemically dependent offenders pass through
the criminal justice system without ever receiving treatment, let alone
MAT.1

A.

06

Drug Dependency and Crime

When it comes to chemically dependent offenders, the lack of proper
treatment in the criminal justice system has a strong correlation to higher rates
of incarceration. In 2017, the South Carolina Department of Corrections
(SCDC) reported 20,951 individuals incarcerated in its facilities across the

103. NAT'L Ass'N OF DRUG COURT PROF'LS, ADULT DRUG COURT BEST PRACTICE
STANDARDS, at 44-45 (text rev. 2018) (citation omitted).
104. NAT. Ass'N OF DRUG COURT PROF'LS, RESOLUTION OF THE BOARD OF DIRECTORS
ON THE AVAILABILITY OF MEDICALLY ASSISTED TREATMENT (M.A.T.) FOR ADDICTION IN

DRUG
COURTS
(2010),
https://ndcrc.org/wp-content/plugins/download-attachments/
includes/download.php?id=3223.
105. NAT'L AsS'N OF DRUG COURT PROF'LS, supra note 103, at 44 (citations omitted).
106. NAT'L INSTS. OF HEALTH, ADDICTION AND THE CRIMINAL JUSTICE SYSTEM 1 (2010)

(citations
omitted),
JusticeSystem(NIDA).pdf.
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state, consisting of 19,491 males and 1,460 females. 107 In its latest census, the
SCDC showed that one-third of the male population (7,122) and over half of
the female population (753) were classified as chemically dependent. 0 A
further analysis of these figures demonstrates that approximately sixty-four
percent of the chemically dependent inmates currently serve sentences for
major crimes, such as murders, burglaries, and armed robberies. 109 This
correlation provides strong evidence that drug dependency plays a major role
in criminal behavior and recidivism. It also highlights the need for states to
explore ways to provide evidence-based treatment to chemically dependent
offenders when they intersect with the criminal justice system. 110
B.

The Sequential Intercept Model

There are five points of intersection in the criminal justice system where
treatment for chemically dependent offenders can make a difference:
deflection, pre-plea diversion, post-plea diversion, post-conviction, and postrelease. These structural points are part of what is known as the Sequential
Intercept Model (SIM). The SIM is a conceptual model that was developed in
2006 by Mark R. Munets, M.D., and Patricia A. Griffin, Ph.D., in
collaboration with the federal Substance Abuse and Mental Health Services
Administration (SAMHSA).'" The SIM envisions these points of
"interception" as opportunities for intervention to prevent chemically
dependent individuals from entering or penetrating deeper into the criminal
justice system. 112 The interception itself has:
several objectives, [such as] preventing initial involvement in the
criminal justice system, decreasing admissions to jail, engaging
individuals in treatment as soon as possible, minimizing time spent
moving through the criminal justice system, linking individuals to

107. Statistical data on file with the Author.
108. Statistical data on file with the Author.
109. Statistical data on file with the Author.
110. Matthias Pierce et al., Insights into the Link Between Drug Use and Criminality:
Lifetime Offending of Criminally-Active Opiate Users, 179 DRUG & ALCOHOL DEPENDENCE,
309, 314, (2017) (citation omitted).
111. Mark R. Munetz & Patricia A. Griffin, Use of the Sequential Intercept Model as an
Approach to DecriminalizationofPeople with Serious Mental Illness, 57 PSYCHIATRIC SERVS.
544, 544 (2006).
112. Id.
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community treatment upon release from incarceration,
decreasing the rate of return to the criminal justice system. 113

867
and

Recognizing its benefits, a growing number of correctional and law
enforcement agencies, as well as prosecutorial entities across South Carolina,
have begun taking notice of the SIM and have steadily increased efforts to
make OUD treatment more accessible at the various points of intersection.
C.

The FirstIntercept:Deflection

Of the five intercept points, the first one involves deflection from the
criminal justice system altogether, leading to an early intervention and access
to treatment. In essence, deflection aims to divert chemically dependent
offenders from arrest, and with the help of law enforcement, direct them to
community-based services without the need to leverage the court through
adjudication." 4 The Law Enforcement Assisted Diversion (LEAD) program
is a great example of a successful deflection model. Originally launched in
2011 in Seattle, Washington, the program is currently implemented in several
other jurisdictions across the country."' The program teaches law
enforcement officers how to exercise their discretionary arresting authority at
the point of contact with chemically dependent offenders for the purpose of
diverting them to community-based treatments or harm-reduction
interventions. This is especially prevalent in cases involving legal violations
that are driven by unmet behavioral health needs.11 6 In a 2017 study of the
program, researchers confirmed significant positive outcomes in LEAD
participants with respect to housing, employment, and income-these
outcomes ultimately resulted in a thirty-three percent reduction in
recidivism. 117 Although law enforcement agencies in South Carolina have yet
to implement a LEAD-model program, the Mount Pleasant Police Department
did develop-and is currently implementing-an opioid-based deflection

113. Id. at 545 (citations omitted).
114. See Substance Abuse and Mental Health Services Administration, Justice
Intervention:Bringing Services to Scale Discussion Guide, RECOVERY MONTH (Dec. 18, 2017),
https://recoverymonth.gov/sites/default/files/roadtorecovery/r2r2018-july-discussion-guide508.pdf.
115. See What is LEAD?, LEAD NAT'L SUPPORT BUREAU, https://www.lead
bureau.org/about-lead (last visited Mar. 29, 2019); About the Bureau, LEAD NAT'L SUPPORT
BUREAU, https://www.leadbureau.org/about-the-bureau (last visited Mar. 29, 2019).
116. What is LEAD?, supra note 115.
117. Seema L. Clifasefi et al., Seattle's Law Enforcement Assisted Diversion (LEAD)
Program: Within-Subjects Changes on Housing, Employment, and Income/Benefits Outcomes
andAssociations with Recidivism, 63 CRIME & DELINQUENCY 429, 429-30 (2017).
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program called First Step. The program began operation in July 2018, and it
aims to prevent opioid-related overdoses by connecting opioid users and their
families with MAT and behavioral treatments." 8
D.

The Second Intercept: Pre-PleaDiversion

While the first intercept operates outside the reach of the court system,
the second, third, and fourth intercepts are all well within the system and as
a result-are more complex to implement. Part of the complexity is due to an
unavoidable gap in time from the moment of arrest to the disposition of the
criminal case. During this gap, the prosecution is ethically discharging its
duties in administering justice via the gathering of case materials and evidence
from the arresting agency, reviewing these files in their entirety, turning them
over to the defense through the discovery process, contacting the victims,
discussing any legal challenges that the defense advances, and finally,
formulating the appropriate plea offer. However, from a treatment
perspective, this gap in time-created by the unavoidable process of
processing a case through our legal system is counterproductive when
addressing opioid-dependent individuals. Defendants who are not able to post
bond remain incarcerated at local detention centers, where they are not only
forced into abstinence, but are also unable to receive the medically adequate
treatment to address their underlying substance use disorder. To complicate
matters even more, opioid-dependent offenders who remain incarcerated for
longer periods of time while remaining abstinent experience a significant
decrease in their opioid tolerance. 119 As a result, once these individuals are
released back into society, they are at an increased risk of drug-related death
especially in the first two to four weeks following release. 120 However,
defendants who are able to post bond are no better positioned to address their
underlying OUD. Concerned defense counsel cannot petition the court for

118. Angie Jackson, Amid Opioid Crisis, Mount Pleasant Police First in SC to Launch
Recovery-Focused
Program,
POST
&
COURIER
(Aug.
5,
2018),
https://www.postandcourier.com/news/amid-opioid-crisis-mount-pleasant-police-first-in-sc-to/
article_0b5a869c-86 lb- 1e8-8709-b7b23 1fe8d4e.html.
119. Elizabeth L. C. Merrall et al., Meta-Analysis of Drug-Related Deaths Soon After
Release from Prison, 105 ADDICTION 1545, 1545 (2010).
120. Sheila M. Bird & Sharon J. Hutchinson, Male Drugs-RelatedDeath in the Fortnight
After Release from Prison: Scotland, 1996-99, 98 ADDICTION 185, 185 (2003) (citing S.R.
Seaman et al., Mortalityfrom Overdose Among Injecting Drug Users Recently Releasedfrom
Prison:DatabaseLinkage Study, 316 BRITISH MED. J. 426, 428 (1998)).
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drug treatment without their clients' consent. 121 As a result, with the absence
of judicial authority to order chemically dependent defendants into treatment
until the time of a plea, they remain at a higher risk of drug overdoses and
recidivism regardless of their ability to post bail.
The second SIM intercept, pre-plea diversion, provides an opportunity to
increase access to treatment notwithstanding the aforementioned time gap.
Although many judicial circuits in the state already operate diversionary
programs, such as Pre-Trial Intervention, Alcohol Education Programs, and
Traffic Education Programs,1 22 the reality is that none of these programs is
adequately equipped to address the complex nature of drug addiction. To
bridge this gap, DAODAS formulated the Medication-Assisted Treatment
Court (MATC) program in 2017.123 By drawing on knowledge and experience
from both the worlds of the judicial system and drug addiction treatment, the
program capitalizes on the judicial time gap. The MATC provides opioiddependent defendants with access to treatment, and it does so with minimal
interruption of the judicial process of pending criminal cases.
MATC commences upon arrest; therefore, it is essential to identify the
appropriate participants prior to setting bond. Since defendants' right to bond
in criminal matters is embedded in the United States Constitution, the South
Carolina Constitution, and the South Carolina Code of Laws, arresting
agencies and intake personnel at the detention centers must work quickly and
efficiently to screen defendants' appropriateness for the program prior to the
defendants' departure from incarceration.124 in some cases, the presence of
opioid dependency is evident from the charges pending against the defendant,
such as possession of heroin or drug paraphernalia. 2 51In other cases, it can be
ascertained from the officers' engagement with individuals they know or

121. See generally MODEL RULES OF PROF'L CONDUCT r. 1.4 (a)(2) (AM. BAR Ass'N
2018) ("A lawyer shall . . . reasonably consult with the client about the means by which the
client's objectives are to be accomplished.").
122. S.C. COMM'N ON PROSECUTION COORDINATION, DIVERSION PROGRAMS OFFERED
BY
THE
OFFICES
OF
SOLICITOR
BY
CIRCUIT
AND
COUNTY
(2018),
https://www.scstatehouse.gov/Committeelnfo/HouseLegislativeOversightCommittee/Agency
Webpages/ProsecutionCoordination/Diversion%20programs%20offered%/o20by%20the%2OCir
cuit%20Solicitors'%200ffices%20(as%20of%o2OJuly%2 202018).pdf.
0
123. S.C. Dep't of Alcohol and Other Drug Abuse Services, South Carolina's MedicationAssisted Treatment Court Project (unpublished proposal) (on file with author).
124. See U.S. CONST. amend. VIII; S.C. CONST. art. 1, § 15; S.C. CODE ANN. § 17-15-10
(Supp. 2018) ("Person charged with noncapital offense may be released on his own
recognizance").
125. S.C. CODE ANN. § 44-53-370(c) (2018) (prohibiting intentional or knowing
possession of a controlled substance unless obtained directly via prescription); Id. § 44-53-391
("It shall be unlawful for any person to advertise for sale, manufacture, possess, sell or deliver
or to possess with the intent to deliver, or sell paraphernalia.").
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recognize-as chemically dependent. However, neither of these methods is
sufficient to identify the vast majority of opioid-dependent individuals who
trickle through the criminal justice system. To standardize the identification
process, MATC utilizes the evidence-based Screening, Brief Intervention, and
Referral to Treatment (SBIRT) model. Developed by professionals at the
Institute of Medicine, SBIRT provides a simple and reliable method for
community-based screening for health risk behaviors, which includes
substance use.1 26 Through a series of short but carefully crafted questions,
intake personnel can identify and flag arrestees with OUD and initiate the
process for their inclusion in MATC.
A positive screen is followed by notification of a Peer Support Specialist
(PSS). A PSS is a man or woman who has experienced the challenges and
successes of the earlier stages of substance use and recovery. The importance
of having a PSS involved with arrested individuals at a point of
incarceration-and throughout the program cannot be understated.
Research recognizes that "[p]eople who have common life experiences also
have a unique capacity to help one another based on a shared affiliation and a
deep understanding that go beyond what exists in their other relationships."1 27
Additionally, well-qualified and vetted peers can "offer their experience,
strength, and hope, which allows for a natural evolution of personal growth,
wellness promotion, and recovery."1 28 Following notification from the
detention center, the PSS-along with a drug treatment counselor meets
with a defendant at the detention center, explains the purpose and goals of
MATC, and conducts a comprehensive assessment to determine the
defendant's level of addiction and proper course of treatment. If a defendant
is diagnosed as appropriate for MATC, the counselor notifies the bond court
prior to the setting of bond.
When determining bond amounts for MATC-appropriate defendants,
bond courts do not deviate from the outlined statutorily-defined criteria.1 29

126. SBIRT: Screening, BriefIntervention, and Referral to Treatment, SAMSHA-HRSA
CTR. FOR INTEGRATED HEALTH

SOLUTIONS, https://www.integration.samhsa.gov/clinical-

practice/sbirt (last visited Mar. 29, 2019).
&

127. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEPT. OF HEALTH
HUMAN SERVS., PUB. SMA- 11-4633, CONSUMER OPERATED SERVICES: THE EVIDENCE 7

(2011) (citation omitted).
128. Id. (citation omitted).
129. As previously stated, in South Carolina, any "[p]erson charged with a non-capital
offense may be released on his own recognizance." § 17-15-10. In cases where personal
recognizance does not reasonably ensure the appearance of the person, or where the person poses
a danger to the community or an individual, the court may impose additional conditions on the
release. These may include requiring the person to post a surety bond, restrictions on travel, or
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Instead, they suspend the original personal recognizance bond in favor of
participation in MATC. This substitution of bonds allows defendants to be
quickly released in order to commence treatment, and safeguards against
penalizing defendants if they "fail out" of the program. Non-compliant MATC
defendants are returned to the detention center for imposition of the original
bond without risking bond revocation altogether. Compliant defendants enjoy
access to MAT as well as behavioral treatment from qualified service
providers. MATC participants also have increased access to ancillary services,
such as housing solutions, transportation to and from court, and employment
assistance. By incorporating the behavioral, medical, and wrap-around
services in a single program, MATC desires to increase defendants'
compliance with the court and reduce the likelihood of overdoses and
recidivism. Inevitably, at the disposition of their criminal charges, MATC
participants can accumulate several months of recovery and avoid recidivism.
They are primed for success either in a drug court program or
alternatively are able to use MATC involvement as a mitigating factor in
traditional plea and sentencing.
The success of a program such as MATC hinges entirely on its
stakeholders' ability to synergistically communicate and collaborate among
themselves. Unlike deflection programs which require fewer entities to
deploy MATC is multi-layered and encompasses numerous stakeholders at
various times throughout the lifespan of the criminal case. These stakeholders
include magistrate and general sessions judges, solicitors and assistant
solicitors, public defenders, law enforcement agencies, county detention
centers, behavioral health treatment providers, physicians, nurse practitioners,
methadone maintenance programs, housing organizations, peer-support
services, and other at-large community partnerships. Consequently, rapid
communication and fostering trust among participating entities is challenging.
In addressing this concern, MATC singles out three primary stakeholders who
are responsible for the day-to-day effective flow of accurate information on
the participants: the solicitor's office, the treatment service provider, and the
PSS. Alternatively, anecdotal stakeholders, such as bond courts or housing
organizations, are consulted as needed and draw upon the information
supplied by the primary stakeholders.
Funding is another major obstacle to developing and implementing a pilot
program such as MATC. In September 2018, the United States Bureau of
Justice Assistance awarded DAODAS a competitive grant to establish the first

placing the person on electronic monitoring. See id. § 17-15-1O(A)(1)-(4) (stating the judge has
discretion to impose any condition he or she deems "reasonably necessary").
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MATC program in York County. 3 0 The grant, which totals $900,000 over a
period of three years, aims to divert at least thirty defendants annually into
treatment from the point of incarceration.' 3 ' The project is a collaboration
between DAODAS, the Sixteenth Judicial Circuit Solicitor's Office, the York
County Sheriffs Office, Keystone Substance Abuse Services (treatment
service provider), Rock Hill Treatment Specialists (methadone maintenance
program), Oxford Houses, Peer Support Specialists trained by Faces and
Voices of Recovery, as well as a research component to be conducted by Dr.
Duane Neff and Dr. Jessica Yang with Winthrop University's Department of
Social Work.' 32 The pilot program's goal is to implement a successful and
practical MATC model that can be duplicated elsewhere in South Carolina.
Moreover, if successful, MATC's blueprints can extend beyond opioids to
provide meaningful alternatives to incarceration for chemically dependent
individuals, irrespective of MAT.
E.

The Third Intercept: Post-PleaDiversion

While MATC addresses gaps in access to treatment from the point of
arrest to disposition, the third sequential intercept, post-plea diversion, strives
to address similar gaps in post-disposition programs, such as drug courts. The
genesis of drug courts is intimately tied to the exponential growth in drug
caseloads in the 1980s. "As a centerpiece of the so-called 'war on drugs,'
elected officials across the nation backed efforts to arrest, prosecute, and
imprison persons possessing or selling illegal drugs. As a result, arrests for
drug-related violations represent the largest single category of police activity,
particularly in the nation's major urban areas."' 3 3 Since the creation of the
first drug court in Dade County, Florida, in 1989, more research has been
published on the effects of drug courts on the criminal justice system than
virtually all other criminal programs combined. 14 According to the NADCP,
the United States boasts over 2,700 drug courts, and the model is implemented
in at least thirteen other countries.' 35 In South Carolina, fifteen out of the
sixteen judicial circuits operate drug courts. However, although the NADCP

130. See U.S. BUREAU OF JUSTICE ASSISTANCE, SOUTH CAROLINA'S MEDICATIONTREATMENT
COURT PROJECT, https://external.ojp.usdoj.gov/selector/award
Detail?awardNumber=2018-AR-BX-KO28&fiscalYear=2018&applicationNumber=2018-H2
059-SC-AR&programOffice=BJA&po=BJA (last visited Feb. 14, 2019).
13 1. See id.
132. See id.
133. DAVID W. NEUBAUER & HENRY F. FRADELLA, AMERICA'S COURTS AND THE
CRIMINAL JUSTICE SYSTEM 97 (13th ed).
134. NAT'L Ass'N OF DRUG COURT PROF'LS, supra note 103, at vi.
135. Id.
ASSISTED
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adopted the position that drug courts should explore the benefits of MAT, only
one judicial circuit-in collaboration with DAODAS-has elected to do so.
Due to the fact that drug courts in South Carolina have been slow to
harness the benefits of MAT, the House Opioid Abuse Prevention Study
Committee recommended in its report that the General Assembly allocate
funding to support MAT-based diversion programs.1 36 In the 2018 legislative
session, the General Assembly followed this recommendation and provided
funding in proviso. The proviso tasks DAODAS to collaborate with a judicial
circuit solicitor's office to establish a program that will provide both
behavioral and medical treatment, consultations with Peer Support
Specialists, and continued supervision of participants.1 37 In late 2018,
DAODAS partnered with the Sixteenth Judicial Circuit Solicitor's Office in
York County to establish a first-of-its-kind MAT-based drug court in South
Carolina.1 38 The court treats ten participants with ranging levels of opioid
dependency for a minimum of eighteen months. It is supervised by the
Honorable Lee S. Alford, who also presides over the Circuit's primary drug
court program. The program incorporates intensive outpatient treatment, to
include all three FDA-approved medications, which are provided by Keystone
Substance Abuse Services (York County's alcohol and drug abuse authority)
and a local methadone maintenance program. Similar to MATC, this MATbased drug court program is augmented with ancillary support services (e.g.,
peer support, housing, transportation) to ensure maximum compliance, low
recidivism, and prevention of drug-related overdoses. From a research
perspective, implementing both MATC and the MAT-based drug court as
successive programs in the same county provides a unique opportunity to
measure a continuum of care within the criminal justice system and its effects
on criminal behavior.
F.

The Fourth and Fifth Intercepts: Post-Convictionand Post-Release

Apart from engagement in pending criminal cases, DAODAS also
recognizes the need to address drug dependency and relapse prevention in a

136. S.C. H.R. OPIOID ABUSE PREVENTION STUDY COMM., FINDINGS AND
RECOMMENDATIONS 23-24 (2018), https://www.scstatehouse.gov/Committeelnfo/HouseOpi
oidAbusePreventionStudyCommittee/House%200pioid%/o20Abuse%20Prevention%20 Study%
20Committee%20Final%2OReport%202018.pdf.
137. H.R. 4950, 122nd Gen. Assemb. 1st Spec. Sess. (S.C. 2018).
138. Press Release, S.C. Dep't Alcohol & Other Drug Abuse Servs., DAODAS Pilots New
Medication-Assisted Treatment Court Concept in York County (Mar. 3, 2019),
http://www.daodas.sc.gov/wp-content/uploads/2019/03/Medication-Assisted-Treatment-Court19-174B.pdf.
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corrections setting. The fourth and fifth intercepts of the SIM, post-conviction
and post-release, contemplate opportunities to increase access to treatment for
incarcerated individuals or those who leave corrections. As discussed supra,
incarcerated populations are especially susceptible to relapse and drug-related
overdoses in post-release. Hence, the benefits of increasing drug treatment in
corrections, especially MAT, are tremendous. Data from a recent study in
Rhode Island that examined the benefits of providing MAT in corrections
facilities demonstrated almost a sixty-one percent decrease in postincarceration deaths. 3 9 Additionally, Rhode Island saw an overall twelve
percent reduction in overdose deaths in the state's general population in the
post-implementation period.1 40 In South Carolina, SCDC has consistently
shown interest in expanding access to evidence-based practices and
developing programs for its incarcerated population.
In November 2017, DAODAS and SCDC started a small-scale pilot
project to provide the opioid-antagonist Vivitrole to inmates prior to their
discharge from SCDC.141 Similar to the program in Rhode Island, the aim of
the South Carolina project is to reduce drug-related mortality rates in the postrelease population. Additionally, the project helps inmates transition back into
the community by connecting them with local treatment providers. At the
heart of the project are two DAODAS Peer Support Specialists who work with
both male and female inmates at various correctional facilities. Enrollment in
the program is voluntary and is irrespective of receiving Vivitrole. To date,
the Peer Support Specialists have worked with over 270 inmates to maximize
their access to treatment while transitioning back into communities across the
state. 142 Out of this group, sixteen have elected to receive Vivitrole prior to
release. The Peer Support Specialists follow up with participants at thirty,
sixty, ninety, and 180 days post-release to evaluate their engagement in
treatment, housing, and employment. The results are promising. Out of the
sixteen who received Vivitrole prior to release, thirteen have secured
transitional housing, and twelve are gainfully employed. The vast majority are
still engaged in treatment and more importantly none has suffered a drug-

139. Traci C. Green et al., PostincarcerationFatal Overdoses After Implementing
MedicationsforAddiction Treatment in a Statewide CorrectionalSystem, 75 J. AM. MED. Ass'N
PSYCHIATRY 405, 406 (2018).
140. Id. at 405-06.
141. Andrew Brown, South Carolina Prisons Attempting Trial Run For New Opioid
Treatment Drug, POST & COURIER (Sep. 4,2017), https://www.postandcourier.com/news/southcarolina-prisons-attempting-trial-run-for-new-opioid-treatment/article_3b559298-8cla-il e7978d-174ab60d0b25.html.
142. S.C. DEPT. OF ALCOHOL & OTHER DRUG ABUSE SERVS., BUDGET REQUEST FISCAL
YEAR 2018-2019 (Jan. 23, 2018).
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related overdose.' 43 Both SCDC and DAODAS are in the process of
expanding the program to reach a wider range of the incarcerated population.
VI. CONCLUSION

For too long, misinformation, judgment, and prejudice took the lead in
treating drug dependency in the United States. As evidenced by the raging
opioid-related public health crisis impacting the nation, years of heavy
criminal penalties for drug crimes and mass incarceration have yielded very
few results in reducing drug addiction or in making communities safer. If
anything, the monstrous size of this epidemic exposed how drug use has
infiltrated the American way of life with utter disregard for race or socioeconomic status. It brought to light not only the shame and stigma of drug use,
but also the insidious greed of those who profited from it. This Article's
highlighted programs demonstrate not only the untapped opportunities for
drug addiction treatment within the criminal justice system, but also the need
to shift resources and reexamine the current prevailing criminal justice
mindset in South Carolina.

143. See generally Harold Blackwell, MAT Program Weekly Client Tracker Log
Weekending, Nov. 16, 2018 (showing no record of overdoses) (on file with author).
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